Description GDC-0980 is designed to be a selective, dual inhibitor of PI3 Kinase and mTOR Kinase. PI3 Kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Development Status Phase I clinical trials evaluating GDC-0980 for solid tumors or non-Hodgkin's lymphoma are ongoing. Phase Ib clinical trials evaluating GDC-0980 in combination with targeted medicines, Avastin® (bevacizumab), Herceptin® (trastuzumab), and Xeloda® (capecitabine) are ongoing or planned. A Phase II clinical trial evaluating both GDC-0941 and GDC-0980 for second-line ER-positive metastatic breast cancer and a Phase II clinical trial in renal cell carcinoma are planned.

This molecule was discovered jointly by Genentech and Piramed Ltd. under a collaboration agreement. Piramed Ltd. was acquired by F. Hoffmann-La Roche.

For Avastin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.avastin.com .

For Herceptin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.herceptin.com .

For Xeloda full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.xeloda.com.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

April 2011